Driving Ability in Adults With ADHD Before and After 10-weeks of Treatment With 40-80mg Atomoxetine vs. Untreated Adults With ADHD.
Phase of Trial: Phase IV
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms DrivPerfATX
- 29 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2011 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 21 Jul 2009 New trial record